IMMUNO-COV
A NEUTRALIZING ANTIBODY TEST
The Test for Antibodies that Block Infection
Receive the deepest level of understanding of the body’s defense status.
The IMMUNO-COV™ neutralizing antibody test is a functional
assay that quantifies the virus-neutralizing function of
antibodies that can stop SARS-CoV-2, the virus
that causes COVID-19.
WHAT'S YOUR TITER?
INQUIRIESSCROLL DOWN
FOR MORE
IMMUNO-COV
A NEUTRALIZING ANTIBODY TEST
The Test for Antibodies that Block Infection
Receive the deepest level of understanding of the body’s defense status. The IMMUNO-COV™ neutralizing antibody test is a functional assay that quantifies the virus-neutralizing function of antibodies that can stop SARS-CoV-2, the virus that causes COVID-19.
WHAT'S YOUR TITER?
IMMUNO-COV™
TEST HIGHLIGHTS
IMMUNO-COV™ is the test for antibodies that block infection of COVID-19. IMMUNO-COV™, a clinically validated, high throughput vesicular stomatitis virus (VSV)-based surrogate virus neutralization assay for the accurate quantitation of SARS-CoV-2 neutralizing antibodies.
Developed by affiliates Imanis and Vyriad, in collaboration with Regeneron.
Virus Neutralizing Titers Correlate to Traditional PRNT Titers
As part of IMMUNO-COV™’s clinical validation, comparison between VNT and traditional Plaque Reduction Neutralization Test (PRNT) was important to confirm effectiveness of the assay, as PRNT is considered the gold standard for serological testing. The comparison confirms a tight correlation between the two assays.
Unlike PRNT, IMMUNO-COV™ is scalable to meet the needs of the COVID-19 global pandemic.
Measures Durability of COVID-19 Immunity After Infection or Vaccination
Neutralizing antibody titers drop rapidly after natural infection. Early IMMUNO-COVTM data indicates that these titers decline at least 50% (and up to 80%) within six months of recovering from COVID-19. Periodic quantitative testing will lead to better understanding the decline in neutralizing antibody titers in both recovered patients and inoculated individuals.
Severity of Illness Does Not Guarantee Level of Immunity
IMMUNO-COV™ data supports the general trend of “more severe sickness = more neutralizing antibodies”, however the data also shows that this is not a guaranteed outcome.
Regardless of illness severity, individuals develop a wide range of neutralizing antibody titers.
IMMUNO-COV™
TEST HIGHLIGHTS
IMMUNO-COV™ is the test for antibodies that block infection of COVID-19. IMMUNO-COV™, a clinically validated, high throughput vesicular stomatitis virus (VSV)-based surrogate virus neutralization assay for the accurate quantitation of SARS-CoV-2 neutralizing antibodies.
Developed by affiliates Imanis and Vyriad, in collaboration with Regeneron.
Virus Neutralizing Titers Correlate to Traditional PRNT Titers
As part of IMMUNO-COV™’s clinical validation, comparison between VNT and traditional Plaque Reduction Neutralization Test (PRNT) was important to confirm effectiveness of the assay, as PRNT is considered the gold standard for serological testing. The comparison confirms a tight correlation between the two assays.
Unlike PRNT, IMMUNO-COV™ is scalable to meet the needs of the COVID-19 global pandemic.
Measures Durability of COVID-19 Immunity After Infection or Vaccination
Neutralizing antibody titers drop rapidly after natural infection. Early IMMUNO-COVTM data indicates that these titers decline at least 50% (and up to 80%) within six months of recovering from COVID-19. Periodic quantitative testing will lead to better understanding the decline in neutralizing antibody titers in both recovered patients and inoculated individuals.
Severity of Illness Does Not Guarantee Level of Immunity
IMMUNO-COV™ data supports the general trend of “more severe sickness = more neutralizing antibodies”, however the data also shows that this is not a guaranteed outcome.
Regardless of illness severity, individuals develop a wide range of neutralizing antibody titers.
IMMUNO-COV™
SO, WHAT'S YOUR TITER?
Neutralizing antibodies are key determinants of protection against COVID-19 infection. While other types of antibodies can bind to the SARS-CoV-2 virus, they cannot inhibit the virus from infecting cells and spreading throughout the body. Only neutralizing antibodies block infection.
And when it comes to defense against infection, there is power in numbers.
“Titer” (quantity) is the measurement of the amount or concentration of a substance (neutralizing antibodies) in a solution (blood). The higher the titer, the stronger the body’s ability to protect against infection.
IMMUNO-COV™
SO, WHAT'S YOUR TITER?
Neutralizing antibodies are key determinants of protection against COVID-19 infection. While other types of antibodies can bind to the SARS-CoV-2 virus, they cannot inhibit the virus from infecting cells and spreading throughout the body. Only neutralizing antibodies block infection.
And when it comes to defense against infection, there is power in numbers.
“Titer” (quantity) is the measurement of the amount or concentration of a substance (neutralizing antibodies) in a solution (blood). The higher the titer, the stronger the body’s ability to protect against infection.
IMMUNO-COV™
APPLICATIONS
IMMUNO-COV™ was developed to address the urgent need to know whether an individual who has recovered from COVID-19 has maintained the protective neutralizing antibodies against the virus. Since its launch, supporting the scientific and research community has been our top priority. As we broaden IMMUNO-COV™’s availability, our support of this community continues in ongoing work on these and other applications:
- Evaluates relative effectiveness of SARS-CoV-2 vaccines in individuals
- Key testing technology for people with prior SARS-CoV-2 infections to assess the strength and durability of their immunity to COVID-19 over time
- Physician ordered tests for patients presumed or suspected to have been exposed to the virus (or a vaccine) more than 2 weeks prior to testing.
COVID-19 Vaccines + Neutralizing Antibodies
All Operation Warp Speed vaccines have been designed to stimulate neutralizing antibody production, as the FDA required neutralizing antibody quantities be measured in vaccine trials as an indication of efficacy.
Measuring Vaccine Efficacy with IMMUNO-COV™
IMMUNO-COVTM can help start to address COVID-19 vaccine-related questions such as:
1. Did the vaccine work?
Vaccines authorized for emergency use are >90% effective, meaning that they are <10% ineffective. Measuring neutralizing antibody titers using quantitative neutralizing antibody tests – such as PRNT or IMMUNO-COVTM – provide valuable insight to vaccine recipients as to whether they fall into the successful (or unsuccessful) category of vaccine efficacy.
2. Can I track my titer over time? Does the vaccine continue to work?
Titers can be tracked when quantitative neutralizing antibody testing is conducted periodically (recommended every 90 days). Antibody titers fall steadily after recovering from COVID-19 and are expected to decline similarly after vaccination, so repeat testing is recommended to confirm the body’s defense status against infection.
The protection provided by neutralizing antibodies will weaken and eventually disappear entirely over time.
IMMUNO-COV™
APPLICATIONS
IMMUNO-COV™ was developed to address the urgent need to know whether an individual who has recovered from COVID-19 has maintained the protective neutralizing antibodies against the virus. Since its launch, supporting the scientific and research community has been our top priority. As we broaden IMMUNO-COV™’s availability, our support of this community continues in ongoing work on these and other applications:
- Evaluates relative effectiveness of SARS-CoV-2 vaccines in individuals
- Key testing technology for people with prior SARS-CoV-2 infections to assess the strength and durability of their immunity to COVID-19 over time
- Physician ordered tests for patients presumed or suspected to have been exposed to the virus (or a vaccine) more than 2 weeks prior to testing.
COVID-19 Vaccines + Neutralizing Antibodies
All Operation Warp Speed vaccines have been designed to stimulate neutralizing antibody production, as the FDA required neutralizing antibody quantities be measured in vaccine trials as an indication of efficacy.
Measuring Vaccine Efficacy with IMMUNO-COV™
IMMUNO-COVTM can help start to address COVID-19 vaccine-related questions such as:
1. Did the vaccine work?
Vaccines authorized for emergency use are >90% effective, meaning that they are <10% ineffective. Measuring neutralizing antibody titers using quantitative neutralizing antibody tests – such as PRNT or IMMUNO-COVTM – provide valuable insight to vaccine recipients as to whether they fall into the successful (or unsuccessful) category of vaccine efficacy.
2. Can I track my titer over time? Does the vaccine continue to work?
Titers can be tracked when quantitative neutralizing antibody testing is conducted periodically (recommended every 90 days). Antibody titers fall steadily after recovering from COVID-19 and are expected to decline similarly after vaccination, so repeat testing is recommended to confirm the body’s defense status against infection.
The protection provided by neutralizing antibodies will weaken and eventually disappear entirely over time.